Drug Profile
Research programme: non-nucleoside reverse transcriptase inhibitors - Tibotec
Alternative Names: NNRTI research programme - Tibotec; Non-nucleoside reverse transcriptase inhibitors research programme - TibotecLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Tibotec BVBA
- Class Pyridones
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in HIV-1-infections in Belgium
- 20 Feb 2008 This programme is still in active development
- 10 Mar 2005 Data presented at the 12th Conference on Retroviruses and Opportunistic Infections (CROI-2005) have been added to the Viral infections pharmacodynamics and antimicrobial section